Appropriate number of plasma exchanges in Guillain-Barre syndrome

Annals of Neurology

Volumn 41, Issue 3, 1997, Pages 298-306

  Raphaël, Jean Claude ^a   Chevret, Sylvie ^b   Chastang, Claude ^b   Jars Guincestre, Marie Claude ^a  

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; ARTIFICIAL VENTILATION; BRADYCARDIA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GUILLAIN BARRE SYNDROME; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE STRENGTH; NEUROLOGIC EXAMINATION; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WALKING;

ADULT; CAUSE OF DEATH; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLASMA EXCHANGE; POLYRADICULONEUROPATHY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031047929     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410410304     Document Type: Article

References (28)

1. Ropper AH, Wijdicks EFM, Truax BT. Guillain Barré syndrome. Contemporary neurology series. Philadelphia: FA Davis, 1991
2. Raphael JC, Masson C, Morice V, et al. Le syndrome de Landry-Guillain-Barré. Etude des facteurs pronostiques dans 223 cas. Rev Neurol 1986;142:613-624
3. Winer JB, Hughes RAC, Osmond C. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988;51:605-612
4. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978;2:750-753
5. Guillain-Barré Syndrome Steroidal Trial Group. Double-blind study of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993;341:586-590
6. Cook SD, Dowling PC, Murray MR, Whitaker JN. Circulating demyelinating factors in acute idiopathic polyneuropathy. Arch Neurol 1971;24:136-144
7. Saida T, Saida K, Lisak RP, et al. In vivo demyelinating activity of serum from patients with Guillain-Barré syndrome. Ann Neurol 1982;11:69-75
8. Harrison BM, Hansen LA, Pollard JD, McLeod JG. Demyelination induced by serum from patients with Guillain-Barré syndrome. Ann Neurol 1984;15:163-170
9. Metral S, Raphael JC, Hort-Legrand C, Elkharrat D. Activité démyélinisante sérique et syndrome de Guillain-Barré: effet favorable des échanges plasmatiques. Rev Neurol 1989;145:312-319
10. Sumner A, Said G, Idy I, Metral S. Effets électrophysiologiques du sérum humain introduit dans l'espace endoneural du nerf sciatique du rat. Résultats préliminaires. Rev Neurol 1982;138: 17-24
11. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22:753-761
12. The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096-1104
13. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Plasma exchange in Guillain-Barré syndrome: one-year follow-up. Ann Neurol 1992;32:94-97
14. Van Der Meché FGA, Schmicz PIM, and the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-1129
15. Consensus conference. The utility of therapeutic plasmapheresis for neurological disorders. J Am Med Assoc 1986;256:1333-1337
16. Raphael JC, Chevret S, Chastang C, Gajdos P. Intravenous immune globulin versus plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;327:816 (Letter)
17. Bleck TP. Treatment strategies for patients with the Guillain-Barré syndrome. Crit Care Med 1993;21:641-643
18. The Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group, Comparison of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in the treatment of Guillain-Barré Syndrome. Ann Neurol 1995;38:972 (Abstract)
19. Asbury AK, Arnason BG, Karp HR, McFarlin DE. Criteria for the diagnosis of Guillain-Barré syndrome. Ann Neurol 1978;3: 565-567
20. Bouget J, Chevret S, Chastang C, et al. Plasma exchange morbidity in Guillain-Barré syndrome: results from the French prospective, double-blind, randomized, multicencer study. Crit Care Med 1993;21:651-658
21. Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Oxford: Blackwell Scientific, 1987
22. Collett D. Modelling survival data in medical research. London: Chapman and Hall, 1994
23. Thorton CA, Griggs RC. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann Neurol 1994;35:260-268
24. Murray NMF, Wiles CM, Karni Y, Newsom-Davis J. Intensive plasma exchange in acute inflammatory polyneuropathy. Ann Med Intern (Paris) 1984;135:144 (Abstract)
25. McKhann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 1988;23:347-353
26. Winer JB, Hughes RAC, Greenwood RJ, et al. Prognosis in Guillain-Barré syndrome. Lancet 1985;1:1202-1203
27. Ropper AH, Albers JW, Addison R. Limited relapse in Guillain-Barré syndrome after plasma exchange. Arch Neurol 1988;45:314-315
28. Osterman PO, Fagius J, Safwenberg J, et al. Early relapses after plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1986;2:1161 (Letter)